Morifuji Masahiko, Murakami Yoshiaki, Yokoyama Yujiro, Sasaki Masaru, Hayashidani Yasuo, Toge Kunio, Sueda Taijiro
Dept. of Surgery, Division of Clinical Medical Science, Graduate School of Biomedical Sciences, Hiroshima University.
Gan To Kagaku Ryoho. 2004 Nov;31(12):2027-30.
We report a case in which chemotherapy with paclitaxel (TXL) infused systemically and intraperitoneally was effective for gastric cancer with malignant ascites. A 69-year-old man suffering from advanced gastric cancer with peritoneal dissemination underwent distal gastrectomy, a radical C operation. After chemotherapy with TS-1 and low-dose CDDP, TS-1 was administrated on an outpatient basis for 6 months. However, he complained of abdominal fullness and ascites, and received combination chemotherapy with paclitaxel infused systemically and intraperitoneally as second-line treatment. The ascites completely disappeared 5 weeks after administration. The only toxic event was anemia (grade 1), and no major adverse effects were observed.
我们报告了一例通过全身和腹腔内注射紫杉醇（TXL）进行化疗对伴有恶性腹水的胃癌有效的病例。一名69岁患有晚期胃癌伴腹膜播散的男性接受了远端胃切除术及根治性C手术。在用替吉奥（TS-1）和低剂量顺铂（CDDP）化疗后，TS-1门诊给药6个月。然而，他主诉腹胀和腹水，并接受了全身和腹腔内注射紫杉醇联合化疗作为二线治疗。给药5周后腹水完全消失。唯一的毒性事件是贫血（1级），未观察到重大不良反应。
